We build cis-targeting biologics to rewire immunity.

Prox Bio is creating medicines that deliver exceptional dosing, safety, and efficacy for patients facing fatal and debilitating diseases. We use next-generation immunology, antibody engineering, and computational methods to control biological pleiotropism.

We’re building a sustainable, efficient drug hunting team to do great translational science. Prox was founded in March 2024 by world-class immunologists and antibody engineers across UCSF, Alloy, Stanford, Penn, and MIT. You can find us in person at LabCentral in Kendall Square.

We’re a Seed-stage biotech company, 9 scientists strong, supported by top biotech investors. Let's build tomorrow's immunotherapies together.